Description

Human Immunoglobulin (pH4) is a high-purity IVIg formulation containing ??95% human IgG monomer/dimer. Prepared via low-temperature ethanol fractionation, viral inactivation, and refined through multi-step purification with additives such as maltose, this 5% solution (2.5?g in 50?ml) is indicated in research models for immune replacement in hypogammaglobulinemia, autoimmune disorders like ITP and Kawasaki disease, severe infection, and primary immunodeficiency. The product modulates immune responses through passive antibody delivery and immunoregulation. Packaged as a single vial. Strictly for laboratory use.

Product Specifications

Mechanism of Action & Research Applications

This IVIg preparation contains broad-spectrum human IgG antibodies, enabling both immune replacement and immune modulation. In laboratory models, Human Immunoglobulin (pH4) is used to elevate total IgG and neutrophil levels rapidly—beneficial in hypogammaglobulinemia studies post-CD20 therapy—and to modulate autoimmune conditions such as ITP and Kawasaki disease by suppressing autoantibody production and cytokine release. It supports research in hematologic oncology, transplantation, and immunodeficiency correction. Clinical consensus supports its dual immunoregulatory and antiviral functions in hematological disease models.

Side Effects (For Reference Only in Research Models)

Experimental and clinical analogue data report minor and transient adverse events: nausea, vomiting, mild rash, and muscle/joint pain in some cases. No severe grade 3+ reactions observed in studied cohorts. These serve as guidance for safety and dosing strategy in research protocols.

Disclaimer

Human Immunoglobulin (pH4) for Intravenous Injection is strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic use.